D. E. Shaw & Co. Inc. Raises Stake in IQVIA Holdings Inc. (NYSE:IQV)

D. E. Shaw & Co. Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 211.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 965,302 shares of the medical research company’s stock after purchasing an additional 655,153 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in IQVIA were worth $189,691,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Howard Capital Management Inc. lifted its position in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after buying an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after acquiring an additional 56 shares during the period. Cypress Wealth Services LLC boosted its holdings in shares of IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 57 shares in the last quarter. Harbor Investment Advisory LLC lifted its position in shares of IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 58 shares during the period. Finally, Magnolia Capital Advisors LLC grew its holdings in shares of IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company’s stock worth $516,000 after buying an additional 74 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the subject of several research analyst reports. HSBC cut IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Mizuho dropped their price target on IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 9th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Morgan Stanley increased their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $231.71.

IQVIA Stock Up 4.8 %

IQV opened at $153.21 on Thursday. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The firm has a market capitalization of $27.01 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a fifty day moving average price of $165.23 and a 200-day moving average price of $189.61.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.77 billion. During the same period last year, the firm earned $2.54 earnings per share. IQVIA’s quarterly revenue was up 2.5% on a year-over-year basis. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.